TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03018626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: rituximab (375 mg/m2) given intravenously (IV) on day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab (375 mg/m2) given intravenously (IV) on day 0

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide(750 mg/m2)/dayg IV on days 5

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: prednisone (100 mg) given orally bid on days 1 through to 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: prednisone (100 mg) given orally bid on days 1 through to 5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vindesine
Description: Vindesine (2 mg/m2) given on days 1 and 5
Study: NCT04213599

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary intervention
Description: Patients with STEMI undergo coronary intervention
Study: NCT00559949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
Study: NCT03465345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin: The starting dose for Metformin is 850mg once a day, the second dose is 850mg once a day; the third dose level is 850mg twice a day; the fourth dose level is 850mg twice a day. Each dose level lasts for 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oligomeric Procyanidin Complex
Description: OPC: The starting dose for OPC is 500mg once a day; the second dose is 1000mg once a day; the third dose level is 1000mg once a day; the fourth dose level is 1500mg once a day. Each dose level lasts for 28 days.
Study: NCT04652817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MMI-22-04-2019
Description: A cross-linked form of the Hyaluronic Acid is used in intradermal injection to augment the labia majora area.
Study: NCT04379713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20-valent pneumococcal conjugate vaccine
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-valent pneumococcal conjugate vaccine
Description: Pneumococcal conjugate vaccine
Study: NCT03399578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 MERS
Description: The ChAdOx1 MERS vaccine consists of the replication-deficient simian adenovirus vector ChAdOx1, containing the MERS Spike protein antigen.
Study: NCT01044394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polyethylene glycol (PEG-ELS) and bisacodyl tablets
Description: 2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
Study: NCT02092337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: computer-assisted speech training
Study: NCT01081340

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social network building intervention
Description: Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home visit
Description: Three home visits during third trimester and three during postpartum period until 6 months postpartum
Study: NCT03942419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.1% Ophthalmic Solution
Description: Atropine 0.1% ophthalmic solution administered with a microdose dispenser

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine 0.01% Ophthalmic Solution
Description: Atropine 0.01% ophthalmic solution administered with a microdose dispenser

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Placebo ophthalmic solution administered with a microdose dispenser
Study: NCT04073017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enterade®
Description: Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enterade®
Description: Participants will drink an 8 ounce bottle of Enterade® twice a day for 4 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)
Description: Ancillary studies
Study: NCT02666560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auditory Cueing
Description: Auditory cueing set at different frequency rates
Study: NCT00060125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00293176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
Study: NCT00003970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT01480089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Ropivacaine (AIR)
Description: Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomized Intraperitoneal Saline (AIS)
Description: Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
Study: NCT06552494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-mHealth program
Description: The intervention group receiving the L-mHealth program plus care as usual. Data will be collected at baseline (T0), 1 months (T1) and 3 months (T2) after the intervention.
Study: NCT01219699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.~Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection
Study: NCT03045419

Intervention type: PROCEDURE
Intervention: gadoxetic acid-enhanced liver MRI
Description: liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid

Intervention type: PROCEDURE
Intervention: gadoxetic acid-enhanced liver MRI
Description: liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
Study: NCT03977116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLGT2
Description: These patients will receive SLGT2 therapy after catheter ablation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These patients will receive placebo therapy after catheter ablation.
Study: NCT02219919

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Group
Description: The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Group
Description: The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
Study: NCT01606163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: 1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: 1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1102
Description: 1. Description: GC1102 IV bolus injection during 10\~ 30 seconds.~2. Amount: group1-3ml, group2-5ml, group3-8ml~3. Subject number: group1-8, group2-8, group3-8~4. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: JW normal saline
Description: 1. Description: Normal saline IV bolus injection through 10\~ 30 seconds.~   * Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.~2. Subject number: 9~3. Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)
Study: NCT03861169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transluminal viscoelastic delivery and trabeculotomy
Description: Ab-interno transluminal viscoelastic delivery and trabeculotomy using OMNI Surgical System
Study: NCT04365400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102
Description: DS102 Epeleuton capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS102
Description: DS102 Epeleuton capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT00509769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine [Kadcyla]
Description: Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
Study: NCT01412034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CER-001
Description: Biweekly infusion
Study: NCT00630188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: You Decide
Description: For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician~For Physicians: a one-time educational session on prostate cancer and the value of shared decision making

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reducing Your Risks in the Crash
Description: Publicly available video on highway safety and reducing individual risks in a crash
Study: NCT01335932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Ganciclovir
Description: For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.~The placebo is an IV solution that does not contain any active medications.
Study: NCT06555354

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA targeted analysis on breast cancer tissues
Description: Total RNA is extracted from tissue sample and selected miRNA quantified by PCR based relative quantification method (QPCR) with a standard curve.

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA targeted analysis on breast cancer tissues
Description: Total RNA is extracted from tissue sample and selected miRNA quantified by PCR based relative quantification method (QPCR) with a standard curve.

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA targeted analysis on plasma samples
Description: miRNAs extracted from plasma samples are analysed by QPCR and/or ddPCR .

Intervention type: DIAGNOSTIC_TEST
Intervention: miRNA profiling of breast cancer tissues
Description: Selected samples from the retrospective cohort are profiled for miRNA expression by using GeneChip® miRNA 4.0 Array.
Study: NCT01998555

Intervention type: OTHER
Group type: OTHER
Intervention: CBT

Intervention type: OTHER
Group type: OTHER
Intervention: CBT
Study: NCT02573818

Intervention type: DEVICE
Intervention: SEDASYS System
Description: propofol sedation with the SEDASYS System
Study: NCT02309580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
Study: NCT00436644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: 1250 mg orally days 1 -28.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 \& 15.
Study: NCT00261053

Intervention type: DRUG
Group type: OTHER
Intervention: i.v. recombinant human C1 inhibitor
Study: NCT01306513

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous bone marrow derived mesenchymal stromal cells
Description: Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
Study: NCT02785718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Haemostasis assays
Study: NCT02015741

Intervention type: DEVICE
Intervention: EEG monitoring with Bispectral Index and NeuroSENSE

Intervention type: BEHAVIORAL
Intervention: Clinical observation
Description: Patients will be observed during awake periods and during natural sleep.
Study: NCT00703625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study: NCT03629119

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Fiber Supplement
Description: Participants will be instructed to consume 1 tea spoon of psyllium per day for 3 months and otherwise maintain their habitual diet. Participants will be asked to keep a diary assessing bowel movement and intestinal symptoms such as bloating and flatulence beginning two weeks prior to the intervention.
Study: NCT04090762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conditional cash transfer
Description: Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.
Study: NCT03018626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: Bleomycin (10 mg) given IV on days 1 and 5
Study: NCT04341675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Sirolimus 6mg daily on Day 1 followed by 2mg daily for the next 13 days for a total treatment duration of 14 days or hospital discharge, whatever happens sooner.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01380158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cup pessary (Bioteque America, Inc)
Description: Placement of cup pessary in the vagina after randomization
Study: NCT00003117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT01249872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE
Description: Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE
Description: Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE
Description: Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Description: Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE
Description: Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE
Description: Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
Study: NCT04090762

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conditional cash transfer
Description: Pregnant women receive cash payments conditioned on their use of prenatal services and use of a health facility for child birth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk information provision
Description: Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Risk information provision
Description: Pregnant women who exhibit characteristics associated with a greater risk of a poor birth outcome - these will be identified from the medical and epidemiological literature - will be informed that they possess these characteristics.
Study: NCT00878722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXD101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXD101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Study: NCT04620018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Subjects received Amoxicillin before surgery, before and after surgery ,and only after surgery.
Study: NCT02375048

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated WBI
Description: Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation
Description: APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
Study: NCT00293176

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive matching placebo tablets.
Study: NCT04073017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Chronic Illness Therapy for Patients with Diarrhea (version 4.0)
Description: Ancillary studies